Actual medication label and appearance may vary
Peptide Treatment
KLOW
Choose a treatment option
The KLOW Blend is an advanced "Quads-Peptide" formulation designed for systemic tissue restoration, immune modulation, and dermal vitality. By integrating KPV with the established regenerative triad of GHK-Cu, BPC-157, and TB-500, this blend targets complex inflammatory pathways and accelerates the healing of skin, connective tissues, and the gut lining.
Check eligibilityThe KLOW Blend is not FDA-approved to diagnose, treat, cure, or prevent any disease or illness.
Why it works
Key benefits
- Deep Dermal Repair: Enhanced elasticity and reduction in systemic inflammatory skin markers.
- Accelerated Soft-Tissue Healing: Synergistic support for tendon, ligament, and muscle recovery.
- Immune Modulation: KPV helps balance the body’s inflammatory signals, making it ideal for those with heightened sensitivity.
- Structural Integrity: Supports the strengthening of the extracellular matrix (ECM) throughout the body.
Based on preclinical and clinical observation
Mechanism
How it works
GHK-Cu (Copper Peptide): Stimulates collagen and elastin production, improves skin firmness, and acts as a potent antioxidant for cellular repair. BPC-157 (Body Protection Compound): Enhances blood flow (angiogenesis) to tendons, ligaments, and muscles while providing protective effects for the gastrointestinal tract. KPV (Lysine-Proline-Valine): A potent anti-inflammatory tripeptide derived from alpha-MSH. It helps "calm" overactive immune responses and has demonstrated antimicrobial properties. TB-500 (Thymosin Beta-4): Promotes cellular migration and flexibility in damaged tissues, helping to reduce scar tissue formation and restore range of motion.
Frequently asked questions
FAQs
Initial improvements in recovery time and reduced localized discomfort may be noticed within the first 2 weeks. Significant improvements in skin texture, gut comfort, or chronic tissue issues typically require 6–12 weeks of consistent therapy to align with natural cellular turnover cycles.
Most individuals tolerate the KLOW Blend well. Potential effects may include: Temporary redness, stinging, or irritation at the injection site (common with GHK-Cu). Mild headache or transient fatigue. Rare: Nausea or a metallic taste in the mouth.
Research & Studies
Evidence at a Glance
- 1.
Dalmasso, G., et al. (2008). KPV, a tripeptide, inhibited IL-1β-induced activation of NF-κB and MAP kinases. Journal of Biological Chemistry.
- 2.
Pickart, L., & Margolina, A. (2018). Regenerative and protective actions of the GHK-Cu peptide. International Journal of Molecular Sciences.
- 3.
Sikiric, P., et al. (2020). Toxicity by NSAIDs. Counteraction by BPC 157. Current Pharmaceutical Design.
- 4.
Smart, N., et al. (2011). Thymosin β4 and angiogenesis: Mode of action and therapeutic potential. Annals of the New York Academy of Sciences.
Interested in KLOW?
Take a short assessment and a licensed provider will review if this treatment is right for you.
Clinical Guidance Disclaimer
The information provided in this document is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. It should never replace sound clinical judgment or personalized advice of a qualified healthcare professional. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment protocol. Never disregard professional medical advice or delay in seeking it because of something you have read in these materials.
Liability & Indemnification
By utilizing this information, the user acknowledges and agrees that REBL and its affiliates, providers, and staff are not liable for any direct, indirect, or consequential damages resulting from the use or misuse of the information provided herein. Any reliance on the materials contained in this document is solely at the user's own risk.
Regulatory Status
The KLOW Blend is a compounded peptide formulation prepared by licensed pharmacies. These peptides are considered investigational and are not FDA-approved for human use or the treatment of any medical condition.
Proprietary Rights & Use Restrictions
This document and its contents are the proprietary property of REBL. Unauthorized use, duplication, reproduction, or distribution of these materials—in whole or in part—without express written consent is strictly prohibited.